Ngā hua rapu - Ana-Isabel Teruel

  • E whakaatu ana i te 1 - 15 hua o te 15
Whakamahine hua
  1. 1
    Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

    Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma mā Bruno Paiva, Joaquín Martínez‐López, María‐Belén Vidriales, María‐Victoria Mateos, María-Ángeles Montalbán, Elena Fernandez-Redondo, Lourdes Alonso, Albert Oriol, Ana-Isabel Teruel, Raquel de Paz, José-Garcia Laraña, Enrique Garcíá Bengoechea, Alejandro Martı́n, Joaquín Díaz Mediavilla, Luis Palomera, Felipe de Arriba, Joan Bladé, Alberto Órfão, Juan José Lahuerta, Jesús F. San Miguel

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality

    Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality mā Joaquín Martínez‐López, Bruno Paiva, Lucía López‐Anglada, María‐Victoria Mateos, María‐Teresa Cedena, María‐Belén Vidriales, María Auxiliadora Sáez-Gómez, Teresa Contreras, Albert Oriol, Inmaculada Rapado, Ana-Isabel Teruel, Lourdes Cordón, María Jesús Blanchard, Enrique Garcíá Bengoechea, Luis Palomera, Felipe de Arriba, Cecilia Cueto-Felgueroso, Alberto Órfão, Joan Bladé, Jesús F. San Miguel, Juan José Lahuerta

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

    GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? mā María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, Ana-Isabel Teruel, Ana López de la Guía, Javier López, Enrique Garcíá Bengoechea, Montserrat Pérez, Rafael Martínez, Luis Palomera, Felipe de Arriba, Yolanda González, José Mariano Hernández, Miquel Granell, José-Luis Bello, Joan Bargay, Francisco‐Javier Peñalver, María-Luisa Martín-Mateos, Bruno Paiva, María-Ángeles Montalbán, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

    Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis mā Bruno Paiva, María‐Victoria Mateos, Luis Ignacio Sánchez‐Abarca, Noemí Puig, María‐Belén Vidriales, Lucía López‐Corral, Luís A. Corchete, Miguel‐Teodoro Hernández, Joan Bargay, Felipe de Arriba, Javier de la Rubia, Ana-Isabel Teruel, Pilar Giraldo, Laura Rosiñol, Felipe Prósper, Albert Oriol, José‐Ángel Hernández‐Rivas, Graça Esteves, Juan José Lahuerta, Joan Bladé, José Antonio Pérez‐Simón, Jesús F. San Miguel

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

    Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM mā María‐Victoria Mateos, Joaquín Martínez‐López, Miguel‐Teodoro Hernández, Enrique M. Ocio, Laura Rosiñol, Rafael Martínez, Ana-Isabel Teruel, Norma C. Gutiérrez, María-Luisa Martín Ramos, Albert Oriol, Joan Bargay, Enrique Garcíá Bengoechea, Yolanda González, Jaime Pérez de Oteyza, Mercedes Gironella, Cristina Encinas, Jesús Martín, Carmen Cabrera, Bruno Paiva, María‐Teresa Cedena, Noemí Puig, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

    Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study mā Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Dolores Hernández‐Maraver, Javier López‐Jiménez, Javier de la Rubia, Miquel Granell, Joan Besalduch, Luis Palomera, Yolanda Campos, Ma Asunción Etxebeste, Joaquı́n Dı́az-Mediavilla, Miguel‐Teodoro Hernández, Felipe de Arriba, Norma C. Gutiérrez, Ma Luisa Martín-Ramos, Ma Teresa Cibeira, Ma Victoria Mateos, Joaquín Martínez‐López, Adrián Alegre, Juan José Lahuerta, Jesús F. San Miguel, Joan Bladé

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial mā María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, Norma C. Gutiérrez, Ana-Isabel Teruel, Ana López de la Guía, Javier López, Enrique Garcíá Bengoechea, Montserrat Pérez, Marta Polo, Luis Palomera, Felipe de Arriba, Yolanda Campos, José-Mariano Hernández, Miquel Granell, José-Luis Bello, Joan Bargay, Francisco‐Javier Peñalver, Josep‐María Ribera, María-Luisa Martín-Mateos, Ramón García‐Sánz, Juan José Lahuerta, Joan Bladé, Jesús F. San Miguel

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

    Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials mā Sara Bringhen, María‐Victoria Mateos, Sonja Zweegman, Alessandra Larocca, Antonietta Falcone, Albert Oriol, Davide Rossi, Maide Cavalli, P. Wijermans, Roberto Ria, Massimo Offidani, Juan José Lahuerta, A. M. Liberati, Roberto Mina, Vincenzo Callea, M. Ronald Schaafsma, Chiara Cerrato, Roberto Marasca, Luca Franceschini, Andrea Evangelista, Ana Isabel Teruel, Bronno van der Holt, Vittorio Montefusco, Giovannino Ciccone, Mario Boccadoro, Jesús F. San Miguel, Pieter Sonneveld, Antonio Palumbo

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

    Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials mā Juan José Lahuerta, Bruno Paiva, María‐Belén Vidriales, Lourdes Cordón, María‐Teresa Cedena, Noemí Puig, Joaquín Martínez‐López, Laura Rosiñol, Norma C. Gutiérrez, María-Luisa Martín-Ramos, Albert Oriol, Ana-Isabel Teruel, M Asuncion Echeveste, Raquel de Paz, Felipe de Arriba, Miguel‐Teodoro Hernández, Luis Palomera, Rafael Martínez, Alejandro Martı́n, Adrián Alegre, Javier de la Rubia, Alberto Órfão, María‐Victoria Mateos, Joan Bladé, Jesús F. San Miguel

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance mā María‐Victoria Mateos, Norma C. Gutiérrez, María-Luisa Martín-Ramos, Bruno Paiva, María-Ángeles Montalbán, Albert Oriol, Joaquín Martínez‐López, Ana-Isabel Teruel, Enrique Garcíá Bengoechea, Alejandro Martı́n, Joaquı́n Dı́az-Mediavilla, Felipe de Arriba, Luis Palomera, José-Mariano Hernández, Anna Sureda, Joan Bargay, Francisco‐Javier Peñalver, Josep‐María Ribera, María-Luisa Martín-Mateos, Manuela Fernández, Ramón García‐Sánz, María‐Belén Vidriales, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

    Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients mā Bruno Paiva, María‐Teresa Cedena, Noemí Puig, Paula Arana, María‐Belén Vidriales, Lourdes Cordón, Juan Flores‐Montero, Norma C. Gutiérrez, María-Luisa Martín-Ramos, Joaquín Martínez‐López, Enrique M. Ocio, Miguel‐Teodoro Hernández, Ana-Isabel Teruel, Laura Rosiñol, M Asuncion Echeveste, Rafael Martínez, Mercedes Gironella, Albert Oriol, Carmen Cabrera, Jesús Martín, Joan Bargay, Cristina Encinas, Yolanda González, Jacques J. M. van Dongen, Alberto Órfão, Joan Bladé, María‐Victoria Mateos, Juan José Lahuerta, Jesús F. San Miguel

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

    Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group mā Sara Alonso, Laura Magnano, Miguel Alcoceba, Marcio Andrade‐Campos, Natalia Espinosa‐Lara, Guillermo Rodríguez‐Domínguez, Santiago Mercadal, Itziar Carro, Juan‐Manuel Sancho, Moreno Miriam, Antonio Salar, Francesc García‐Pallarols, Reyes Arranz, Jimena Cannata, María José Terol, Ana Isabel Teruel, Antonia Rodríguez, Ana Jiménez Ubieto, Sonia González de Villambrosía, José Belló, Lourdes López, Silvia Monsalvo, Silvana Novelli, Erik de Cabo, María Stefanía Infante, Emilia Pardal, María García‐Álvarez, Julio Delgado, Marcos González, Alejandro Martı́n, Armando López‐Guillermo, Marı́a Dolores Caballero

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

    GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethason... mā María‐Victoria Mateos, Bruno Paiva, María Teresa Cedena Romero, Noemí Puig, Anna Maria Sureda Balarí, Albert Oriol, Enrique M. Ocio, Laura Rosiñol, Yolanda González-Montes, Juan Bargay, Esther González García, Miguel Teodoro Hernández Garcia, Angel Ramirez, Alexia Suárez-Cabrera, María‐Jesús Blanchard, Sebastián Garzón, Luis Felipe Casado Montero, Valentín Cabañas Perianes, Jaime Pérez de Oteyza, Mercedes Gironella, Joaquín Martínez‐López, Ana-Isabel Teruel, Pilar Delgado, Elena Prieto, Juan José Lahuerta Palacios, Joan Bladé, Jesús F. San Miguel

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance mā María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero, Verónica González‐Calle, Marta Sonia González, Albert Oriol, Norma C. Gutiérrez, Rafael Ríos, Laura Rosiñol, Miguel Angel Alvarez Rivas, Joan Bargay, Ana Pilar González-Rodríguez, Adrián Alegre, Fernando Escalante, María Belén Iñigo Rodríguez, Javier de la Rubia, Ana Isabel Teruel, Felipe de Arriba, Luis Palomera, Miguel‐Teodoro Hernández, Javier López‐Jiménez, Marta Reinoso‐Segura, Aránzazu García Mateo, Enrique M. Ocio, Bruno Paiva, Noemí Puig, María‐Teresa Cedena, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel

    I whakaputaina 2024
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

    Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd an... mā María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero, Verónica González‐Calle, Marta Sonia González, Albert Oriol, Norma C. Gutiérrez, Bruno Paiva, Rafael Ríos Tamayo, Laura Rosiñol Dachs, Miguel Ángel Álvarez-Avitia, Marı́a José Calasanz, Joan Bargay, Ana Pilar González-Rodríguez, Adrián Alegre Amor, Fernando Escalante, Belén Íñigo, Noemí Puig, Javier de la Rubia, Ana Isabel Teruel, María Teresa Cedena Romero, Felipe de Arriba, Luis Palomera, Miguel‐Teodoro Hernández, Javier López Jiménez, Jesús Martín, Aránzazu García Mateo, Enrique M. Ocio, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: